Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (rAAV) is derived from a small human parvovirus with an excellent safety profile. In addition, this viral vector efficiently transduces and supports long-term transgene expression in the nervous system. These properties make rAAV a reasonable candidate vector for treating neurological disorders. Indeed, rAAV is currently being used in five early stage clinical trials for various neurodegenerative disorders. Therefore, we will review the currently available preclinical data using rAAV in animal models of central nervous system (CNS) disorders. Moreover, potential caveats for rAAV-based gene therapy in the CNS are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · cited 1×
“Previously AD research has been dominated by the hypothesis that the memory deficits in AD were caused by the specific loss of a group of cells in the basal forebrain that have widely diffuse projections to the cerebral cortex and use acetylcholine (ACh) as their neurotransmitter [76].”
BackgroundTight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“A number of artificial regulation systems have been developed for the control of transgene expression in vivo, including the tetracycline [211], ecdysone [212], progesterone antagonist mifepristone [213], and rapamycin systems [214].”
BackgroundMangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557 · cited 1×
“Microglia are the immune cells of the central nervous system and can exist in activated or resting states [164].”
BackgroundDirect brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
The changing landscape of ischaemic brain injury mechanisms
Lee, J.-M., Zipfel, G. J., & Choi, D. W. (1999) · Nature · doi:10.1038/399a007 · Cited by 1,102
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 1×
“Nevertheless, these preclinical data and positive data from a clinical trial in which NGFtransduced autologous fibroblasts were transplanted into the basal forebrain of AD patients [84] have spawned a rAAV-NGF phase I clinical trial in AD sponsored by Ceregene, Inc [4].”
BackgroundRetrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872 · cited 6×
“This is the first such report of reliable rAAV2 transport from the muscle to the spinal cord although the frequency was admittedly inefficient in [166] and nonexistent in [27] (even though the reported injection titers were almost identical).”
BackgroundMethodInfluentialBurger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
Self-citationImmune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684 · cited 1×
“There are reports of a lower incidence of nAB’s to other AAV serotypes in the human population [222].”
BackgroundHarper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682 · cited 6×
“Along these lines, rAAV1mediated short hairpin RNAs (shRNA’s) targeted to specific regions of the htt mRNA, delivered intrastriatally to a transgenic HD mouse, reduced both the cellular phenotype and the behavioral phenotype onset [113] (Figs.”
BackgroundResultInfluentialAAV serotype 2 vectors preferentially integrate into active genes in mice
Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A. (2003) · Nature Genetics · doi:10.1038/ng1179 · Cited by 392 · cited 1×
“Interestingly, the recombinant version of AAV loses much of its capacity to integrate and the genome persists in an episomal form [9,10].”
BackgroundThomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358
Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model
Luo, J., Kaplitt, M. G., Fitzsimons, H. L., Zuzga, D. S., Liu, Y., Oshinsky, M. L., & During, M. J. (2002) · Science · doi:10.1126/science.1074549 · Cited by 325 · cited 2×
“rAAV-GAD-treated 6-OHDA-lesioned rats were reported to recover after subthalamic injections [68].”
BackgroundRemote control of gene transcription
West, A. G., & Fraser, P. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi104 · Cited by 302
Regulatable gene expression systems for gene therapy applications: progress and future challenges
Goverdhana, S., Puntel, M., Xiong, W., Zirger, J. M., Barcia, C., Curtin, J. F., Soffer, E. B., Mondkar, S., King, G. D., Hu, J., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.022 · Cited by 283 · cited 1×
“The different regulation systems that are available for gene therapy applications and in the context of AAV have been discussed in several recent reviews in great detail [6,221].”
BackgroundJanson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128612 · Cited by 255
Peden, C. S., Burger, C., Muzyczka, N., & Mandel, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6344-6359.2004 · Cited by 222
Self-citationChannelopathies as a genetic cause of epilepsy
Mulley, J. C., Scheffer, I. E., Petrou, S., & Berkovic, S. F. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200304000-00009 · Cited by 214 · cited 2×
“Idiopathic epilepsies are the most common forms of the disorder, although the genes mutated in familial types of seizures and epilepsies are beginning to be identified, and about 25 single gene mutations have been described to date [191,192].”
BackgroundViral Gene Delivery Selectively Restores Feeding and Prevents Lethality of Dopamine-Deficient Mice
Szczypka, M. S., Mandel, R. J., Donahue, B. A., Snyder, R. O., Leff, S. E., & Palmiter, R. D. (1999) · Neuron · doi:10.1016/s0896-6273(00)80688-1 · Cited by 129
Self-citationAAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis
Griffey, M., Macauley, S. L., Ogilvie, J. M., & Sands, M. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.018 · Cited by 115
Recombinant Adeno-Associated Viral Vectors in the Nervous System
Burger, C., Nash, K., & Mandel, R. J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.781 · Cited by 110 · cited 4×
“Very early in the development of rAAV as a viral vector, it was discovered that this vector is highly efficient in the nervous system and infects mainly neurons [5,6,12].”
BackgroundMethodInfluentialSelf-citationStriatal Delivery of rAAV-hAADC to Rats with Preexisting Immunity to AAV
Sanftner, L. M., Suzuki, B. M., Doroudchi, M. M., Feng, L., McClelland, A., Forsayeth, J. R., & Cunningham, J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.005 · Cited by 89
Amyloid β-Peptide: The Inside Story
Tseng, B., Kitazawa, M., & LaFerla, F. (2004) · Current Alzheimer Research · doi:10.2174/1567205043332045 · Cited by 72
Klugmann, M., Leichtlein, C. B., Symes, C. W., Serikawa, T., Young, D., & During, M. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.006 · Cited by 55 · cited 1×
“reported no clinically relevant benefit after brain injection of rAAV-ASPA [177].”
BackgroundHeusner, C. L., Hnasko, T. S., Szczypka, M. S., Liu, Y., During, M. J., & Palmiter, R. D. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02986-x · Cited by 48
Cited by
Klein, R. L., Dayton, R. D., Tatom, J. B., Henderson, K. M., & Henning, P. P. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300331 · Cited by 196
Gene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
Markusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131
Reimsnider, S., Manfredsson, F. P., Muzyczka, N., & Mandel, R. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300227 · Cited by 125
Self-citationTowne, C., Schneider, B. L., Kieran, D., Redmond, D. E., & Aebischer, P. (2010) · Gene Therapy · doi:10.1038/gt.2009.119 · Cited by 124
Metadata
- Authors
- Mandel, R. J., Manfredsson, F. P., Foust, K. D., Rising, A., Reimsnider, S., Nash, K., & Burger, C.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 13
- Issue
- 3
- Pages
- 463-483
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2034860964
- Cited by
- 126
- References
- 27
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.